Overview

A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

Status:
Not yet recruiting

Trial end date:
2026-06-30

Target enrollment:

Participant gender:

Summary

This is an open label, multi-center, single arm study to evaluate the efficacy and safety of tislelizumab combined with sitravatinib as adjuvant therapy in hepatocellular carcinoma (HCC) patients who are at high risk of recurrence after curative resection.

Phase:

Phase 2

Details

Lead Sponsor:

Anhui Provincial Hospital

Collaborators:

First Affiliated Hospital of Guangxi Medical University
First Affiliated Hospital Xi'an Jiaotong University
Zhejiang Cancer Hospital